Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BREVICON 28-DAY vs ALYACEN 1/35
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive; ethinyl estradiol and norethindrone suppress gonadotropin secretion (FSH and LH) via negative feedback, inhibiting ovulation. Additionally, alters cervical mucus consistency and endometrial lining to impede sperm penetration and implantation.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.
Prevention of pregnancy,Acne vulgaris (off-label in some guidelines),Menstrual cycle irregularities (off-label)
Prevention of pregnancy
One tablet (0.5 mg norethindrone and 35 mcg ethinyl estradiol) orally once daily for 28 days (21 active tablets followed by 7 inert tablets).
One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
Norethindrone: 8-11 hours; Ethinyl estradiol: 13-27 hours; half-life for ethinyl estradiol allows once-daily dosing
Norethindrone: 8-11 hours (terminal); ethinyl estradiol: 10-20 hours (terminal). The half-life supports once-daily dosing for oral contraceptive efficacy.
Hepatic; ethinyl estradiol metabolized primarily via CYP3A4; norethindrone metabolized via reduction and conjugation (sulfation and glucuronidation).
Ethinyl estradiol: primarily hepatic via CYP3A4; norethindrone: hepatic reduction and sulfate conjugation.
Renal: ~40% as metabolites and unchanged drug; fecal/biliary: ~60% as metabolites
Renal excretion of metabolites (primarily ethinyl estradiol and norethindrone conjugates) accounts for approximately 50-60% of elimination; fecal excretion accounts for 30-40%. Unchanged drug excretion is minimal (<5%).
Norethindrone: ~61% bound to albumin and SHBG; Ethinyl estradiol: ~97% bound to albumin
Norethindrone: 61% bound to albumin and SHBG; ethinyl estradiol: 97-98% bound to albumin.
Norethindrone: 4 L/kg; Ethinyl estradiol: 2-4 L/kg; indicates extensive tissue distribution
Norethindrone: 3.8-4.5 L/kg; ethinyl estradiol: 2.0-4.0 L/kg. Large Vd indicates extensive tissue distribution.
Oral: ~64% for norethindrone; ~40% for ethinyl estradiol due to first-pass metabolism
Oral: Norethindrone ~64%, ethinyl estradiol ~38-48% (due to first-pass metabolism).
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (GFR <30 m L/min) or dialysis, use is not recommended due to potential fluid retention and hypertension.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential fluid retention and electrolyte disturbances.
Contraindicated in acute hepatic disease, cholestatic jaundice of pregnancy or prior oral contraceptive use, or severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), use is not recommended unless benefits outweigh risks; close monitoring of hepatic function advised.
Contraindicated in patients with hepatic impairment, including Child-Pugh class B or C, due to impaired metabolism of estrogen and progestin. Not recommended in patients with active liver disease or history of liver tumors.
Safety and efficacy in postmenarchal adolescents are established. Dosing is the same as adults: one tablet orally once daily for 28 days. Use before menarche is not indicated.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults. Safety and efficacy established for contraception; weight-based dosing not applicable.
Not indicated for use in postmenopausal women. No specific dosing adjustments are provided for elderly patients as the drug is not intended for this population.
Not indicated for use after menopause due to lack of benefit and increased risks (e.g., cardiovascular, thromboembolic events). If used, monitor for fluid retention, hypertension, and glucose intolerance.
Cigarette smoking increases risk of serious cardiovascular events from oral contraceptive use. Risk increases with age (especially in women over 35 years) and with number of cigarettes smoked. Women who use oral contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Increased risk of thromboembolic events (especially in smokers, obese, or hypertension), myocardial infarction, stroke, hepatic neoplasia, gallbladder disease, hypertension, and carbohydrate/lipid metabolism effects. Should be discontinued if jaundice, visual disturbances, or migraine occur. May decrease bone density in long-term use.
Thrombotic disorders (e.g., DVT, PE, stroke, MI),Cerebrovascular disease,Hepatic neoplasia,Gallbladder disease,Hypertension,Carbohydrate and lipid effects,Ocular lesions,Hereditary angioedema,Chloasma,Menstrual irregularities,Pregnancy exclusion prior to initiation
Known or suspected pregnancy; history of thrombophlebitis, thromboembolic disorders, or cerebrovascular disease; current or history of breast cancer or estrogen-dependent neoplasia; undiagnosed abnormal genital bleeding; hepatic adenoma or carcinoma; known or suspected hypersensitivity to components; use with Hepatitis C combination therapy containing ombitasvir/paritaprevir/ritonavir with or without dasabuvir.
Venous or arterial thrombotic/thromboembolic disease (current or history),Cerebrovascular disease,Coronary artery disease,Known or suspected breast cancer,Endometrial or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Smoking in women over 35
Grapefruit juice may increase ethinyl estradiol levels; avoid excessive consumption. No other significant food interactions.
No significant food interactions. Grapefruit juice may increase estrogen levels, but clinically not a concern. Avoid excessive alcohol, which may impair liver function and increase estrogen exposure. Maintain a healthy diet, as weight gain is possible.
Pregnancy category X. Estrogen/progestin combination contraceptives are contraindicated in pregnancy due to risk of fetal harm, including cardiovascular and limb defects, particularly in the first trimester. Use in second and third trimesters is associated with increased risk of fetal genital tract abnormalities and other adverse outcomes.
Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including cardiovascular defects and limb reduction defects. Second/third trimesters: Potential for urogenital abnormalities and feminization of male fetus. Exposure is associated with subsequent development of clear cell adenocarcinoma of vagina/cervix in female offspring (DES-related).
Excreted in breast milk in small amounts; may reduce milk production and affect infant. M/P ratio not established for Brevicon. Use is not recommended during breastfeeding due to potential for adverse effects on the infant and lactation.
Small amounts of contraceptive steroids and/or metabolites have been identified in breast milk. M/P ratio: Not specifically determined for this combination; ethinyl estradiol M/P ratio ~0.02-0.04. Use may reduce milk production and quality. Breastfeeding not recommended during use. Alternative contraception advised.
Contraindicated in pregnancy; no dose adjustment recommended. Discontinue immediately if pregnancy is suspected or confirmed. No pharmacokinetic changes require dose adjustments because use during pregnancy is prohibited.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue medication immediately upon pregnancy detection.
Breakthrough bleeding is common in first 3 cycles; counsel patients to continue dosing. Efficacy may be reduced with strong CYP3A4 inducers (e.g., rifampin, carbamazepine, St. John's wort). If vomiting occurs within 3-4 hours of dose, use backup contraception. Consistent timing of daily dose reduces pregnancy risk.
ALYACEN 1/35 is a combination oral contraceptive containing ethinyl estradiol 35 mcg and norgestimate 1 mg. It is indicated for the prevention of pregnancy and for the treatment of moderate acne vulgaris in females ≥15 years of age who desire an oral contraceptive. Monitor for thromboembolic events, especially in smokers over 35 or those with migraine with aura. Use with caution in patients with liver impairment or history of cholestatic jaundice. The pill-free interval should not exceed 7 days; missed pills increase ovulation risk. Consider non-hormonal backup if vomiting or diarrhea occurs within 4 hours of dosing.
Take one tablet daily at the same time, even if you don't have sex that day.,Use back-up contraception (e.g., condoms) if you miss a pill or start late.,Breakthrough spotting may occur, especially in the first few months; do not stop taking your pills.,Smoking increases risk of serious cardiovascular side effects, especially if over 35 years old.,Check pill package for inactive (placebo) pills in the last week.
Take one tablet daily at the same time each day; do not skip doses.,Use an additional non-hormonal contraceptive (e.g., condoms) if you miss a pill, have vomiting, or diarrhea.,Smoking while on this pill increases the risk of blood clots and stroke, especially if you are over 35.,Contact your healthcare provider immediately if you have chest pain, leg pain/swelling, sudden vision changes, or severe headache.,This medication does not protect against HIV or other sexually transmitted infections.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BREVICON 28-DAY vs ALYACEN 1/35, answered by our medical review team.
BREVICON 28-DAY is a Oral Contraceptive that works by Combination oral contraceptive; ethinyl estradiol and norethindrone suppress gonadotropin secretion (FSH and LH) via negative feedback, inhibiting ovulation. Additionally, alters cervical mucus consistency and endometrial lining to impede sperm penetration and implantation.. ALYACEN 1/35 is a Oral Contraceptive that works by Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BREVICON 28-DAY and ALYACEN 1/35 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BREVICON 28-DAY is: One tablet (0.5 mg norethindrone and 35 mcg ethinyl estradiol) orally once daily for 28 days (21 active tablets followed by 7 inert tablets).. The standard adult dose of ALYACEN 1/35 is: One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BREVICON 28-DAY and ALYACEN 1/35 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BREVICON 28-DAY is classified as Category C. Pregnancy category X. Estrogen/progestin combination contraceptives are contraindicated in pregnancy due to risk of fetal harm, including cardiovascular and limb defects, particula. ALYACEN 1/35 is classified as Category C. Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.